CCQ Graphic: Development and validation of a modified Clinical COPD questionnaire for patients with limited health literacy

Clinical Research Results Abstract Research Idea Abstract Service Development & Evaluation Abstract AimTo develop and validate a modified version of the Clinical COPD questionnaire (CCQ) which is more suitable for all patients, including patient with low health literacy (CCQ graphic). The items of the CCQ graphic questionnaire will be complemented with graphics and phrased in comprehensible language, and subsequently validated.Outline of contextThe CCQ is widely used to monitor the disease course and symptoms of COPD. CCQ completion may pose difficulties for patients with low health literacy. This is an important concern as 46% of Dutch COPD patients have low health literacy (Nivel, 2019).Description of change including strategyThis project consists of three phases.Phase 1 (completed): The CCQ graphic was developed by an expert group. Thereupon, it was further optimized through cognitive debriefing with 13 COPD patients with low literacy. Phase 2 (ongoing): The CCQ graphic will be validated in 100 patients with COPD from primary and secondary care who have good health literacy (Health Literacy Survey (HLS) ≥13). The results of the CCQ graphic will be compared with the original CCQ.Phase 3 (ongoing): The reliability of the CCQ graphic will be examined in 40 patients with COPD and limited health literacy (HLS<13). Figure 1 provides a schematic overview of the second and third study phase and all questionnaires.Lessons learned and messageBy developing a CCQ graphic, COPD care will become more inclusive. Which might result in better personalized treatment options for patients with limited health literacy. Results of this study will show whether the modified CCQ is valid for use in daily care. Figure 2 shows the first two items of the CCQ Graphic. The results of the validation and reliability will be presented during the IPCRG conference. Declaration of Interest Dr. Kocks reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Chiesi Pharmaceuticals, grants, personal fees and non-financial support from GSK, grants from Mundi Pharma, grants and personal fees from TEVA, personal fees from MSD, personal fees from COVIS Pharma, outside the submitted work; and Janwillem Kocks holds 72.5% of shares in the General Practitioners Research Institute.In the past three years (2019-2021), GPRI conducted research funded by non- commercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva). References and Clinical Trial Registry Information Heins M, Spreeuwenberg P, Heijmans M, Leven met een longziekte in Nederland 2018, NIVEL / longfonds rapport